Segers Vincent F M, Tokunou Tomotake, Higgins Luke J, MacGillivray Catherine, Gannon Joseph, Lee Richard T
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA.
Circulation. 2007 Oct 9;116(15):1683-92. doi: 10.1161/CIRCULATIONAHA.107.718718. Epub 2007 Sep 17.
Local delivery of chemotactic factors represents a novel approach to tissue regeneration. However, successful chemokine protein delivery is challenged by barriers including the rapid diffusion of chemokines and cleavage of chemokines by proteases that are activated in injured tissues. Stromal cell-derived factor-1 (SDF-1) is a well-characterized chemokine for attracting stem cells and thus a strong candidate for promoting regeneration. However, SDF-1 is cleaved by exopeptidases and matrix metalloproteinase-2, generating a neurotoxin implicated in some forms of dementia.
We designed a new chemokine called S-SDF-1(S4V) that is resistant to matrix metalloproteinase-2 and exopeptidase cleavage but retains chemotactic bioactivity, reducing the neurotoxic potential of native SDF-1. To deliver S-SDF-1(S4V), we expressed and purified fusion proteins to tether the chemokine to self-assembling peptides, which form nanofibers and allow local delivery. Intramyocardial delivery of S-SDF-1(S4V) after myocardial infarction recruited CXCR4+/c-Kit+ stem cells (46+/-7 to 119+/-18 cells per section) and increased capillary density (from 169+/-42 to 283+/-27 per 1 mm2). Furthermore, in a randomized, blinded study of 176 rats with myocardial infarction, nanofiber delivery of the protease-resistant S-SDF-1(S4V) improved cardiac function (ejection fraction increased from 34.0+/-2.5% to 50.7+/-3.1%), whereas native SDF-1 had no beneficial effects.
The combined advances of a new, protease-resistant SDF-1 and nanofiber-mediated delivery promoted recruitment of stem cells and improved cardiac function after myocardial infarction. These data demonstrate that driving chemotaxis of stem cells by local chemokine delivery is a promising new strategy for tissue regeneration.
趋化因子的局部递送是组织再生的一种新方法。然而,趋化因子蛋白的成功递送面临诸多障碍,包括趋化因子的快速扩散以及在损伤组织中被激活的蛋白酶对趋化因子的裂解。基质细胞衍生因子-1(SDF-1)是一种特性明确的趋化因子,可吸引干细胞,因此是促进再生的有力候选因子。然而,SDF-1会被外肽酶和基质金属蛋白酶-2裂解,产生一种与某些形式的痴呆有关的神经毒素。
我们设计了一种名为S-SDF-1(S4V)的新型趋化因子,它对基质金属蛋白酶-2和外肽酶的裂解具有抗性,但保留了趋化生物活性,降低了天然SDF-1的神经毒性潜力。为了递送S-SDF-1(S4V),我们表达并纯化了融合蛋白,将趋化因子与自组装肽连接起来,自组装肽形成纳米纤维并实现局部递送。心肌梗死后心肌内递送S-SDF-1(S4V)可募集CXCR4+/c-Kit+干细胞(每切片46±7至119±18个细胞)并增加毛细血管密度(从每1平方毫米169±42个增加至283±27个)。此外,在一项对176只心肌梗死大鼠的随机、盲法研究中,纳米纤维递送抗蛋白酶的S-SDF-1(S4V)可改善心脏功能(射血分数从34.0±2.5%增加至50.7±3.1%),而天然SDF-1则没有有益效果。
新型抗蛋白酶SDF-1与纳米纤维介导递送的联合进展促进了干细胞的募集并改善了心肌梗死后的心脏功能。这些数据表明,通过局部趋化因子递送驱动干细胞趋化是一种有前景的组织再生新策略。